title: [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
abstract: Epirubicin hydrochloride injection is indicated as a therapy for patients with primary breast cancer. This drug has been reclassified as a drug with high emetic potential according to the American Society of Clinical Oncology Guidelines for Antiemetics in Oncology. Therefore, patients who receive this agent should also receive fosaprepitant dimeglumine, an anti-emetic agent. However, it has been reported that fosaprepitant induces vascular pain when used in anthracycline-based regimens administered via the peripheral veins. In order to relieve the fosaprepitant and epirubicin-induced vascular pain associated with vasculitis, dexamethasone was administered at the onset of vascular pain. There is a possibility that the fosaprepitant and epirubicin-induced pain may improve owing to the administration of dexamethasone; however, further trials are required to confirm the effect of this method.
authors.affiliation: Dept. of Pharmacy, National Hospital Organization Kure Medical Center and Chugoku Cancer Center.
authors.forename: Keita
authors.initials: K
authors.lastname: Kameda
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Kiba
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Shizue
authors.initials: S
authors.lastname: Kimoto
authors.forename: Sayoko
authors.initials: S
authors.lastname: Kajiume
authors.forename: Yuuko
authors.initials: Y
authors.lastname: Okada
authors.forename: Nao
authors.initials: N
authors.lastname: Morii
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Ichiba
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yamashiro
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control; D055815:Young Adult
chemical_list: D000932:Antiemetics; D009025:Morpholines; D015251:Epirubicin; C579707:fosaprepitant; D003907:Dexamethasone